SavedAdd your journal

Journals / art / 2021 / Cilt: 36 - Sayı: 1

Is there any association between low level of serum nesfatin-1 and fibromyalgia syndrome?

Birşen BİLGİCİ
Yeşim AKYOL
Yasemin ULUS
Sebati Sinan ÜRKMEZ
Ömer KURU
Journal
art
Pages
38–46
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In addition, nesfatin-1 may also be involved in the mediation of anxiety-related responses in FMS.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: This study aims to investigate the relationship between serum level of nesfatin-1 and fibromyalgia syndrome (FMS) clinical parameters such as pain severity, disease activity, fatigue, emotional state, and sleep quality.
📊
Key Findings & Data:Patients and methods: Forty-six female patients with FMS (median age: 40 years; range, 18 to 53 years) and 46 healthy female controls (median age: 36 years; range, 19 to 52 years) were included in the study.
💡
Conclusion & Impact:In addition, nesfatin-1 may also be involved in the mediation of anxiety-related responses in FMS.
🔬Design:Survey & Empirical Study
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Objectives: This study aims to investigate the relationship between serum level of nesfatin-1 and fibromyalgia syndrome (FMS) clinical parameters such as pain severity, disease activity, fatigue, emotional state, and sleep quality. Patients and methods: Forty-six female patients with FMS (median age: 40 years; range, 18 to 53 years) and 46 healthy female controls (median age: 36 years; range, 19 to 52 years) were included in the study. Severity of pain, disease activity, fatigue, sleep quality, and emotional status were evaluated by Visual Analog Scale, Fibromyalgia Impact Questionnaire, Multidimensional Assessment of Fatigue (MAF), Pittsburgh Sleep Quality Index (PSQI), Beck Depression Inventory (BDI), and Beck Anxiety Inventory (BAI), respectively. Serum nesfatin-1 concentrations (pg/mL) were measured by enzyme-linked immunosorbent assay method. Results: There was no significant difference with respect to demographic characteristics between the FMS patients and healthy controls. When clinical parameters were compared, MAF, BDI, BAI, and PSQI scores were significantly higher in FMS patients than controls (p<0.05). Serum nesfatin-1 concentration was significantly lower in patients with FMS (p<0.05). When compared to the FMS patients without anxiety, serum nesfatin-1 concentration was significantly increased in FMS patients with anxiety (p<0.05). Serum nesfatin-1 concentration was positively correlated with BAI scores in patients with FMS (p<0.05). Conclusion: Low nesfatin-1 serum levels may contribute to pathological changes in FMS. In addition, nesfatin-1 may also be involved in the mediation of anxiety-related responses in FMS.

🔖

Cite This Article

BİLGİCİ, B., AKYOL, Y., ULUS, Y., ÜRKMEZ, S. S., KURU, Ö. (2021). Is there any association between low level of serum nesfatin-1 and fibromyalgia syndrome?. art, Cilt: 36 - Sayı: 1, 38–46. https://ajindex.com/articles/351634

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Branco JC, Bannwarth B, Failde I, Abello Carbonell J, Blotman F, et al. Prevalence of fibromyalgia: a survey in five European countries. Semin Arthritis Rheum 2010;39:448-53
  2. Berger A, Dukes E, Martin S, Edelsberg J, Oster G. Characteristics and healthcare costs of patients with fibromyalgia syndrome. Int J Clin Pract 2007;61:1498-508
  3. Talotta R, Bazzichi L, Di Franco M, Casale R, Batticciotto A, Gerardi MC, et al. One year in review 2017: fibromyalgia. Clin Exp Rheumatol 2017;35:6-12
  4. Clauw DJ. Fibromyalgia: an overview. Am J Med 2009;122:S3-S13
  5. Alves B, Zakka TM, Teixeira MJ, Kaziyama HH, Siqueira JT, Siqueira SR. Depression, sexuality and fibromyalgia syndrome: clinical findings and correlation to hematological parameters. Arq Neuropsiquiatr 2016;74:863-8
  6. Bhargava J, Hurley JA. Fibromyalgia. StatPearls Publishing. Available at: https://www.ncbi.nlm.nih. gov/books/NBK540974/ [Accessed: November 29, 2019] 7. Oh-I S, Shimizu H, Satoh T, Okada S, Adachi S, Inoue K, et al. Identification of nesfatin-1 as a satiety molecule in the hypothalamus. Nature 2006;443:709-12
  7. Stengel A, Taché Y. Nesfatin-1--role as possible new potent regulator of food intake. Regul Pept 2010;163:18-23
  8. Stengel A. Nesfatin-1 - More than a food intake regulatory peptide. Peptides 2015;72:175-83
  9. Prinz P, Stengel A. Expression and regulation of peripheral NUCB2/nesfatin-1. Curr Opin Pharmacol 2016;31:25-30
  10. Dore R, Levata L, Lehnert H, Schulz C. Nesfatin-1: functions and physiology of a novel regulatory peptide. J Endocrinol 2017;232:R45-R65
  11. Yin Y, Li Z, Gao L, Li Y, Zhao J, Zhang W. AMPKdependent modulation of hepatic lipid metabolism by nesfatin-1. Mol Cell Endocrinol 2015;417:20-6
  12. Merali Z, Cayer C, Kent P, Anisman H. Nesfatin-1 increases anxiety- and fear-related behaviors in the rat. Psychopharmacology 2008;201:115-23
  13. Hofmann T, Ahnis A, Elbelt U, Rose M, Klapp BF, Stengel A. NUCB2/nesfatin-1 Is Associated with Elevated Levels of Anxiety in Anorexia Nervosa. PLoS One 2015;10:e0132058
  14. Gunay H, Tutuncu R, Aydin S, Dag E, Abasli D. Decreased plasma nesfatin-1 levels in patients with generalized anxiety disorder. Psychoneuroendocrinology 2012;37:1949-53
  15. Jego S, Salvert D, Renouard L, Mori M, Goutagny R, Luppi PH, et al. Tuberal hypothalamic neurons secreting the satiety molecule Nesfatin-1 are critically involved in paradoxical (REM) sleep homeostasis. PLoS One 2012;7:e52525
  16. Vas S, Ádori C, Könczöl K, Kátai Z, Pap D, Papp